Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2015 | Research article

Elevated expression of periostin in diabetic cardiomyopathy and the effect of valsartan

Authors: Jun Guan, Wen-Qi Liu, Ming-Qing Xing, Yue Shi, Xue-Ying Tan, Chang-Qing Jiang, Hong-Yan Dai

Published in: BMC Cardiovascular Disorders | Issue 1/2015

Abstract

Background

Periostin, an extracellular matrix protein, plays a significant role in adverse cardiac remodeling. However, no report has documented the function of periostin in left ventricular remodeling of streptozototin (STZ)-induced diabetic rats. The aim of the present study was to observe the expression of periostin in Wistar rat’s myocardium of diabetic cardiomyopathy (DCM) and the effect of valsartan on it.

Methods

Immunohistochemistry, real-time polymerase chain reaction, and Western blot analysis were used to determine the degree of expression and location of periostin, transforming growth factor (TGF)-β1, TGF-β1 type II receptor (TGF-β1 R II), and Type I and III collagens in the myocardium of STZ-induced diabetic rats.

Results

Periostin, TGF-β1, TGF-β1 R II, and Type I and III collagens were significantly increased in the myocardium of diabetic rats compared with control group on both messenger ribonucleic acid and protein levels. In addition, diabetic rats treated with valsartan could have reduced expression of periostin and improved cardiac remodeling of DCM.

Conclusions

Periostin may play a crucial role in cardiac remodeling and myocardial interstitial fibrosis process of DCM and it could be one of the important mechanisms for valsartan to improve the ventricular remodeling of DCM.

Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis [J]. Am J Cardiol. 1972;30(6):595–602.CrossRefPubMed

Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options [J]. Am J Med. 2008;121(9):748–57.CrossRefPubMed

Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications [J]. Endocr Rev. 2004;25(4):543–67.CrossRefPubMed

Fischer VW, Barner HB, Larose LS. Pathomorphologic aspects of muscular tissue in diabetes mellitus [J]. Hum Pathol. 1984;15(12):1127–36.CrossRefPubMed

Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor β [J]. J Bone Miner Res. 1999;14(7):1239–49.CrossRefPubMed

Kruzynska-Frejtag A, Machnicki M, Rogers R, Markwald RR, Conway SJ. Periostin (an osteoblast-specific factor) is expressed within the embryonic mouse heart during valve formation [J]. Mech Dev. 2001;103(1):183–8.CrossRefPubMed

Zhao S, Wu H, Xia W, Chen X, Zhu S, Zhang S, et al. Periostin expression is upregulated and associated with myocardial fibrosis in human failing hearts [J]. J Cardiol. 2014;63(5):373–8.CrossRefPubMed

Katsuragi N, Morishita R, Nakamura N, Ochiai T, Taniyama Y, Hasegawa Y, et al. Periostin as a novel factor responsible for ventricular dilation [J]. Circulation. 2004;110(13):1806–13.CrossRefPubMed

Stansfield WE, Andersen NM, Tang RH, Selzman CH. Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart [J]. Ann Thorac Surg. 2009;88(6):1916–21.CrossRefPubMedPubMedCentral

10.

Ladage D, Yaniz-Galende E, Rapti K, Ishikawa K, Tilemann L, Shapiro S, et al. Stimulating myocardial regeneration with periostin Peptide in large mammals improves function post-myocardial infarction but increases myocardial fibrosis [J]. PLoS One. 2013;8(5):e59656.CrossRefPubMedPubMedCentral

11.

Iekushi K, Taniyama Y, Azuma J, Katsuragi N, Dosaka N, Sanada F, et al. Novel mechanisms of valsartan on the treatment of acute myocardial infarction through inhibition of the antiadhesion molecule periostin [J]. Hypertension. 2007;49(6):1409–14.CrossRefPubMed

12.

Conway SJ, Molkentin JD. Periostin as a heterofunctional regulator of cardiac development and disease [J]. Curr Genomics. 2008;9(8):548.CrossRefPubMedPubMedCentral

13.

Norris RA, Moreno-Rodriguez R, Hoffman S, Markwald RR. The many facets of the matricelluar protein periostin during cardiac development, remodeling, and pathophysiology [J]. Journal of cell communication and signaling. 2009;3(3-4):275–86.CrossRefPubMedPubMedCentral

14.

Snider P, Standley KN, Wang J, Azhar M, Doetschman T, Conway SJ. Origin of cardiac fibroblasts and the role of periostin [J]. Circ Res. 2009;105(10):934–47.CrossRefPubMedPubMedCentral

15.

Zou P, Wu LL, Wu D, Fan D, Cui XB, Zhou Y, et al. High glucose increases periostin expression and the related signal pathway in adult rat cardiac fibroblasts [J]. Sheng Li Xue Bao. 2010;62(3):247–54.PubMed

16.

Yang ZH, Peng XD. Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus [J]. Chin Med J (Engl). 2010;123(24):3640–3.

17.

Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, et al. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent [J]. Lab Invest. 2000;80:513–27.CrossRefPubMed

18.

Li L, Fan D, Wang C, Wang JY, Cui XB, Wu D, et al. Angiotensin II increases periostin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-β1 pathways in cardiac fibroblasts [J]. Cardiovasc Res. 2011;91(1):80–9.CrossRefPubMed

19.

Crawford J1, Nygard K, Gan BS, O'Gorman DB. Periostin induces fibroblast proliferation and myofibroblast persistence in hypertrophic scarring [J]. Exp Dermatol. 2014 Nov 24. doi:10.1111/exd.12601.

20.

Hai-feng ZHANG, Feng WANG, Hong Sun, Mingming Xue. Effects of Pioglitazone on AngII、SOD、NO in Cardiac Hypertrophic Rats [J]. Inner Mongolia Med J. 2013;45(9):1031–3.

21.

Westermann D, Walther T, Savvatis K, Escher F, Sobirey M, Riad A, et al. Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy [J]. Diabetes. 2009;58(6):1373–81.CrossRefPubMedPubMedCentral

22.

Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling [J]. Pharmacol Ther. 2009;123(2):255–78.CrossRefPubMed

23.

Murarka S, Movahed MR. Diabetic cardiomyopathy [J]. J Card Fail. 2010;16(12):971–9.CrossRefPubMed

24.

TSCHÖPE C, Walther T, KÖNIGER J, Spillmann F, Westermann D, Escher F, et al. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene [J]. FASEB J. 2004;18(7):828–35.CrossRefPubMed

25.

Dai HY, Guo XG, Ge ZM, Li ZH, Yu XJ, Tang MX, et al. Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy [J]. J Diabetes Complications. 2008;22(2):137–43.CrossRefPubMed

26.

Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, Sargent MA, et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling [J]. Circ Res. 2007;101(3):313–21.CrossRefPubMedPubMedCentral

27.

Norris RA, Borg TK, Butcher JT, Baudino TA, Banerjee I, Markwald RR. Neonatal and adult cardiovascular pathophysiological remodeling and repair: developmental role of periostin [J]. Ann N Y Acad Sci. 2008;1123:30–40.CrossRefPubMed

28.

Crawford J, Nygard K, Gan BS, O'Gorman DB. Periostin induces fibroblast proliferation and myofibroblast persistence in hypertrophic scarring [J]. Exp Dermatol. 2014 Nov 24. doi:10.1111/exd.12601.

29.

Ren J, Davidoff AJ. Diabetes rapidly induces contractile dysfunctionsin isolated ventricular myocytes [J]. Am J Physiol Heart Circ Physiol. 1997;272:148–58.

30.

Carley AN, DL S s. Fatty acid metabolism is enhanced in type 2 diabetic hearts [J]. Biochim Biophys Acta JT-Biochimicaet Biophysica Acta. 2005;1734(2):112.CrossRef

31.

Feng Z, Qiutang Z, Bingong L, Shuguo L. The alterations of peroxisome proliferator-activated receptor alpha ( PPARα) and free fatty acids in STZ-induced diabetic cardiomyopathy rats [J]. Central China Medical Journal. 2007;31(5):364–6.

32.

Khatter JC, Sadri P, Zhang M, Hoeschen RJ. Myocardial angiotensin II (Ang II) receptors in diabetic rats [J]. Ann N Y Acad Sci. 1996;793:466–72.CrossRefPubMed

33.

Sechi LA, Griffin CA, Schambelan M. The cardiac renin–angiotensin system in STZ-induced diabetes. Diabetes [J]. 1994;43:1180–4.CrossRef

34.

Kim S, Wanibuchi H, Hamaguchi A, Miura K, Yamanaka S, Iwao H. Angiotensin blockade improves cardiac and renal complications of type II diabetic rats [J]. Hypertension. 1997;30:1054–61.CrossRefPubMed

35.

Chan P, Wong KL, Liu IM, Tzeng TF, Yang TL, Cheng JT. Anti-hyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats [J]. J Hypertens. 2003;21(4):761–9.CrossRefPubMed

Title: Elevated expression of periostin in diabetic cardiomyopathy and the effect of valsartan
Authors: Jun Guan
Wen-Qi Liu
Ming-Qing Xing
Yue Shi
Xue-Ying Tan
Chang-Qing Jiang
Hong-Yan Dai
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Cardiovascular Disorders / Issue 1/2015
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-015-0084-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Elevated expression of periostin in diabetic cardiomyopathy and the effect of valsartan

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment

Angina at Low heart rate And Risk of imminent Myocardial infarction (the ALARM study): a prospective, observational proof-of-concept study

Triptolide improves systolic function and myocardial energy metabolism of diabetic cardiomyopathy in streptozotocin-induced diabetic rats

Telerehab III: a multi-center randomized, controlled trial investigating the long-term effectiveness of a comprehensive cardiac telerehabilitation program - Rationale and study design

Prevalence and factors associated with inappropriate use of treadmill exercise stress test for coronary artery disease: a cross-sectional study

Pharmacist intervention in the prevention of heart failure for high-risk elderly patients in the community

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page